title: The spectrum of reactive hemophagocytic syndrome in systemic lupus erythematosus.
abstract: We address the relationship between reactive hemophagocytic syndrome (RHS), systemic lupus erythematosus (SLE) activity, and treatment in 4 female patients with SLE. Febrile pancytopenia was related to cytologically proven RHS in all patients. Followup was 45+/-7 months from RHS onset. No causal infection could be identified. Outcome could be classified as: (1) RHS onset during a SLE flare and complete efficacy of high dose steroids; (2) death despite therapy for concomitant severe RHS and active SLE; (3) severe RHS in inactive SLE under immunosuppressants, with remission after steroid tapering and cyclophosphamide withdrawal. Three patients were treated with intravenous IgG. We conclude that (1) when SLE is active, RHS should be considered a specific manifestation and treated with steroids; (2) RHS occurring in otherwise inactive SLE might be related to iatrogenic immunosuppression; (3) intravenous IgG treatment might be indicated in both situations.
authors.affiliation: Internal Medicine Unit, Pitié-Salpêtière Hospital, Paris, France. thomas.papo@psl.ap-hop-paris.fr
authors.forename: T
authors.initials: T
authors.lastname: Papo
authors.forename: M H
authors.initials: MH
authors.lastname: Andre
authors.forename: Z
authors.initials: Z
authors.lastname: Amoura
authors.forename: O
authors.initials: O
authors.lastname: Lortholary
authors.forename: B
authors.initials: B
authors.lastname: Tribout
authors.forename: L
authors.initials: L
authors.lastname: Guillevin
authors.forename: J C
authors.initials: JC
authors.lastname: Piette
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016913:Blood Component Transfusion; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D015616:Histiocytosis, Non-Langerhans-Cell / Q000209:etiology* / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000628:therapy; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D003520:Cyclophosphamide; D000212:Acyclovir